Eligard 22,5 mg poeder en oplosmiddel voor oplossing voor injectie
RT2019-13
Phase 3 small_molecule active
Quick answer
Eligard 22,5 mg poeder en oplosmiddel voor oplossing voor injectie for Patients with biochemical recurrence after primary treatment of prostate cancer presenting with =<4 metastases is a Phase 3 program (small_molecule) at Disc Medicine with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Disc Medicine
- Indication
- Patients with biochemical recurrence after primary treatment of prostate cancer presenting with =<4 metastases
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active